{"id":5815,"date":"2024-12-17T17:38:43","date_gmt":"2024-12-17T16:38:43","guid":{"rendered":"https:\/\/www.ffrdiabete.org\/?p=5815"},"modified":"2024-12-17T17:57:04","modified_gmt":"2024-12-17T16:57:04","slug":"webconference-on-23-january-2","status":"publish","type":"post","link":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/","title":{"rendered":"A promising avenue for the treatment of MASH!"},"content":{"rendered":"<p><span style=\"color: #143877; font-family: Calibri, sans-serif; font-size: large;\">Have you heard of <strong>MASH<\/strong> ((Metabolic Associated SteatoHepatitis)? Previously known as NASH (Non-Alcoholic SteatoHepatitis). <\/span><\/p>\n<div><span style=\"color: #143877; font-family: Calibri, sans-serif; font-size: large;\"><strong>MASH<\/strong>, closely linked to <strong>obesity<\/strong> and <strong>type 2 diabetes<\/strong> epidemic, is a silent disease that has become a major cause of severe liver conditions like cirrhosis and hepatocellular carcinoma.<br \/>\n&nbsp;<br \/>\n<\/span><\/div>\n<div><\/div>\n<div><\/div>\n<h4 style=\"text-align: center;\"><strong>What are the solutions?<br \/>\n<\/strong><\/h4>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.diabetologie-pratique.com\/actualites\/diabetes-experts-review\/0043460-piste-prometteuse-traitement-mash-survodutide\" target=\"_blank\" rel=\"noopener\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-5789\" src=\"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Capture-decran-2024-12-09-a-12.50.04-1024x1014.png\" alt=\"\" width=\"624\" height=\"618\" srcset=\"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Capture-decran-2024-12-09-a-12.50.04-1024x1014.png 1024w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Capture-decran-2024-12-09-a-12.50.04-300x297.png 300w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Capture-decran-2024-12-09-a-12.50.04-150x150.png 150w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Capture-decran-2024-12-09-a-12.50.04-768x760.png 768w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Capture-decran-2024-12-09-a-12.50.04.png 1210w\" sizes=\"auto, (max-width: 624px) 100vw, 624px\" \/><\/strong><\/a><\/p>\n<p style=\"text-align: left;\">Despite preventive and therapeutic efforts, no fully specific and effective treatment is yet available for MASH:<\/p>\n<ul>\n<li><strong>Pioglitazone<\/strong> is no longer marketed in France&#8230;<\/li>\n<li><strong>GLP1 agonists<\/strong> and <strong>bariatric surgery<\/strong> (weight loss) habe shown some benefits, but&#8230;<\/li>\n<li><strong>Resmetirom<\/strong> targets specific adults with a particular type of fibrosis&#8230;<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Prof. Bernard BAUDUCEAU<\/strong>, former Head of the Endocrinology Department at BEGIN Hospital and <strong>Treasurer of the FFRD<\/strong> <strong>from 2013 to 2021<\/strong>, discusses a new promising avenue: <strong>survodutide<\/strong>, a dual agonist of glucagon and GLP-1 receptors&#8230; The highly encourging results from this trial would require phase 3 studies to confirm its therapeutic potential.<\/p>\n<p><em>Article from Diabetes Experts Review in Diab\u00e9tologie Pratique.<\/em><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/DiabetologiePratique_FFRD-12_BB_Une-piste-prometteuse-pour-le-traitement-de-la-MASH-le-survodutide.pdf\" target=\"_blank\" rel=\"noopener\"><strong>DISCOVER THIS ARTICLE!<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Have you heard of MASH ((Metabolic Associated SteatoHepatitis)? Previously known as NASH (Non-Alcoholic SteatoHepatitis). MASH, closely linked to obesity and type 2 diabetes epidemic, is a silent disease that has become a major cause of severe liver conditions like cirrhosis and hepatocellular carcinoma. &nbsp; What are the solutions? &nbsp; Despite preventive and therapeutic efforts, no&hellip;<\/p>\n","protected":false},"author":2,"featured_media":5825,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee","category-1","description-off"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A promising avenue for the treatment of MASH! - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A promising avenue for the treatment of MASH! - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\" \/>\n<meta property=\"og:description\" content=\"Have you heard of MASH ((Metabolic Associated SteatoHepatitis)? Previously known as NASH (Non-Alcoholic SteatoHepatitis). MASH, closely linked to obesity and type 2 diabetes epidemic, is a silent disease that has become a major cause of severe liver conditions like cirrhosis and hepatocellular carcinoma. &nbsp; What are the solutions? &nbsp; Despite preventive and therapeutic efforts, no&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-17T16:38:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-17T16:57:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Le-survodutide-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1626\" \/>\n\t<meta property=\"og:image:height\" content=\"1128\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"St\u00e9phanie NOUGARET\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FondationFFRD\" \/>\n<meta name=\"twitter:site\" content=\"@FondationFFRD\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"St\u00e9phanie NOUGARET\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/\"},\"author\":{\"name\":\"St\u00e9phanie NOUGARET\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/person\\\/011078a0c444e305b94c3b4630b66d8c\"},\"headline\":\"A promising avenue for the treatment of MASH!\",\"datePublished\":\"2024-12-17T16:38:43+00:00\",\"dateModified\":\"2024-12-17T16:57:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/\"},\"wordCount\":163,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/Le-survodutide-1.jpg\",\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/\",\"name\":\"A promising avenue for the treatment of MASH! - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/Le-survodutide-1.jpg\",\"datePublished\":\"2024-12-17T16:38:43+00:00\",\"dateModified\":\"2024-12-17T16:57:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/Le-survodutide-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/Le-survodutide-1.jpg\",\"width\":1626,\"height\":1128,\"caption\":\"Screenshot\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/webconference-on-23-january-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A promising avenue for the treatment of MASH!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/\",\"name\":\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\",\"description\":\"Pour que la recherche sur le diab\u00e8te avance\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#organization\"},\"alternateName\":\"FFRD\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#organization\",\"name\":\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\",\"alternateName\":\"FFRD\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/FFRD-logo-main-retrina.png\",\"contentUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/FFRD-logo-main-retrina.png\",\"width\":462,\"height\":211,\"caption\":\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/FondationFFRD\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/fondation-francophone-pour-la-recherche-sur-le-diabte---ffrd\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/person\\\/011078a0c444e305b94c3b4630b66d8c\",\"name\":\"St\u00e9phanie NOUGARET\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g\",\"caption\":\"St\u00e9phanie NOUGARET\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A promising avenue for the treatment of MASH! - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/","og_locale":"en_US","og_type":"article","og_title":"A promising avenue for the treatment of MASH! - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","og_description":"Have you heard of MASH ((Metabolic Associated SteatoHepatitis)? Previously known as NASH (Non-Alcoholic SteatoHepatitis). MASH, closely linked to obesity and type 2 diabetes epidemic, is a silent disease that has become a major cause of severe liver conditions like cirrhosis and hepatocellular carcinoma. &nbsp; What are the solutions? &nbsp; Despite preventive and therapeutic efforts, no&hellip;","og_url":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/","og_site_name":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","article_published_time":"2024-12-17T16:38:43+00:00","article_modified_time":"2024-12-17T16:57:04+00:00","og_image":[{"width":1626,"height":1128,"url":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Le-survodutide-1.jpg","type":"image\/jpeg"}],"author":"St\u00e9phanie NOUGARET","twitter_card":"summary_large_image","twitter_creator":"@FondationFFRD","twitter_site":"@FondationFFRD","twitter_misc":{"Written by":"St\u00e9phanie NOUGARET","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/#article","isPartOf":{"@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/"},"author":{"name":"St\u00e9phanie NOUGARET","@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/person\/011078a0c444e305b94c3b4630b66d8c"},"headline":"A promising avenue for the treatment of MASH!","datePublished":"2024-12-17T16:38:43+00:00","dateModified":"2024-12-17T16:57:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/"},"wordCount":163,"publisher":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#organization"},"image":{"@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Le-survodutide-1.jpg","articleSection":["Non classifi\u00e9(e)"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/","url":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/","name":"A promising avenue for the treatment of MASH! - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","isPartOf":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/#primaryimage"},"image":{"@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Le-survodutide-1.jpg","datePublished":"2024-12-17T16:38:43+00:00","dateModified":"2024-12-17T16:57:04+00:00","breadcrumb":{"@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/#primaryimage","url":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Le-survodutide-1.jpg","contentUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2024\/12\/Le-survodutide-1.jpg","width":1626,"height":1128,"caption":"Screenshot"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ffrdiabete.org\/en\/webconference-on-23-january-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ffrdiabete.org\/en\/"},{"@type":"ListItem","position":2,"name":"A promising avenue for the treatment of MASH!"}]},{"@type":"WebSite","@id":"https:\/\/www.ffrdiabete.org\/en\/#website","url":"https:\/\/www.ffrdiabete.org\/en\/","name":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","description":"Pour que la recherche sur le diab\u00e8te avance","publisher":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#organization"},"alternateName":"FFRD","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ffrdiabete.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ffrdiabete.org\/en\/#organization","name":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","alternateName":"FFRD","url":"https:\/\/www.ffrdiabete.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2023\/08\/FFRD-logo-main-retrina.png","contentUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2023\/08\/FFRD-logo-main-retrina.png","width":462,"height":211,"caption":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD"},"image":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/FondationFFRD","https:\/\/www.linkedin.com\/company\/fondation-francophone-pour-la-recherche-sur-le-diabte---ffrd\/"]},{"@type":"Person","@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/person\/011078a0c444e305b94c3b4630b66d8c","name":"St\u00e9phanie NOUGARET","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g","caption":"St\u00e9phanie NOUGARET"}}]}},"_links":{"self":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts\/5815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/comments?post=5815"}],"version-history":[{"count":3,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts\/5815\/revisions"}],"predecessor-version":[{"id":5831,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts\/5815\/revisions\/5831"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/media\/5825"}],"wp:attachment":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/media?parent=5815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/categories?post=5815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/tags?post=5815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}